文献速递流行病学与生物统计临床试验与 GCP

2,109项随机肿瘤试验描绘50年间无进展生存期与总生存期持续但微弱的改善

2,109 randomized oncology trials map continuous, meager improvements in progression-free and overall survival over 50 years.
PubMed 文献 · J Clin Epidemiol · 2022-06-28

该研究通过检索PubMed上的肿瘤网络Meta分析(截至2021年9月30日),提取随机对照试验中系统性治疗的风险比,评估总生存期与无进展生存期治疗效应的模式和时间趋势。共纳入来自241项网络Meta分析的2,109项唯一合格随机对照试验,发现总生存期风险平均降低12%-14%,无进展生存期风险平均降低27%-30%,但仅五分之一试验达到总生存期临床有意义改善标准。

要点

  • 总生存期风险平均降低12%-14%,无进展生存期风险平均降低27%-30%。
  • 总生存期与无进展生存期治疗效应相关性 modest(r=0.60,95%CI 0.56-0.64)。
  • 仅五分之一试验达到总生存期临床有意义改善标准。

核心结论

  • 过去50年肿瘤研究广泛模式提示持续进展,但少数结果达到总生存期临床有意义改善阈值。

研究设计与样本

  • 检索PubMed上的肿瘤网络Meta分析(截至2021年9月30日),从随机对照试验中提取系统性治疗的相关风险比,去除重复结果后分析治疗效应与发表年份、试验设计等特征的关系。

主要发现

  • 来自241项肿瘤网络Meta分析的2,109项唯一合格随机对照试验提供可分析数据。
  • 总生存期风险平均降低12%-14%,无进展生存期风险平均降低27%-30%,不同恶性肿瘤间存在显著异质性。
  • 总生存期与无进展生存期治疗效应相关性 modest(r=0.60,95%置信区间0.56-0.64)。
  • 随时间推移,无进展生存期治疗效应呈提示性增加趋势,而总生存期治疗效应保持稳定。
  • 仅五分之一试验达到总生存期临床有意义改善标准;在300项随机选取的试验中,中位无进展生存期平均绝对改善为1.6个月,中位总生存期平均绝对改善为1.4个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the patterns and time trends in overall survival and progression-free survival treatment effects across randomized controlled trials (RCTs) in oncology. STUDY DESIGN AND SETTING: A PubMed search for oncology network meta-analyses (NMAs) was carried (to September 30, 2021). Relevant hazard ratios were extracted for systemic treatments from RCTs in the NMAs. After removing duplicate results, relationships between treatment effects, year of publication, trial design, and other features were explored. RESULTS: From 241 oncology NMAs, 2,109 unique eligible RCTs provided analyzable data. On average, there was a 12%-14% reduction in hazard for overall survival and 27%-30% reduction for progression-free survival, with substantial heterogeneity across different malignancies. Correlation between overall survival and progression-free survival treatment effects was modest (r = 0.60, 95% confidence interval, 0.56-0.64). Over time, there was a suggestive trend of increased progression-free survival treatment effect, although overall survival treatment effects remained steady. Only one in five trials met criteria for clinically meaningful improvements in overall survival. Among 300 randomly selected trials, mean absolute improvement was 1.6 months for median progression-free survival and 1.4 months for median overall survival. CONCLUSION: Broad patterns across the past 50 years of oncology research suggest continuous progress has been made, but few results meet clinically meaningful thresholds for overall survival improvement.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Parish AJ, Alina Cristea I, Schuit E, et al. 2,109 randomized oncology trials map continuous, meager improvements in progression-free and overall survival over 50 years. J Clin Epidemiol. 2022. PMID: 35777712. doi:10.1016/j.jclinepi.2022.06.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。